GO:0015816 glycine transport: Genes and Methods

Glycine is the simplest amino acid and serves dual roles as an inhibitory neurotransmitter in the spinal cord and brainstem and as a co-agonist at NMDA-type glutamate receptors. The biological process GO:0015816, glycine transport, encompasses the directed movement of glycine across cellular membranes by dedicated transporter proteins or pores. Because glycine cannot freely diffuse across lipid bilayers, its spatial and temporal distribution depends on membrane transport proteins that terminate or shape glycinergic and glutamatergic signaling. Understanding glycine transport is therefore central to neuropharmacology, synaptic physiology, and metabolic disease research. The molecular machinery of glycine transport is dominated by the SLC6 family of sodium- and chloride-dependent neurotransmitter transporters, particularly GlyT1 (SLC6A9) and GlyT2 (SLC6A5). GlyT1 is expressed in glial cells and some neurons, where it clears glycine from the synaptic cleft and regulates NMDA receptor co-agonism. GlyT2 is expressed in glycinergic neurons and replenishes vesicular glycine stores required for inhibitory neurotransmission. Structural and pharmacological studies have revealed distinct transport mechanisms, inhibitor binding sites, and allosteric modulation by membrane lipids for these transporters. Beyond neurotransmission, glycine transport intersects with creatine metabolism because the glycine cleavage system and glycine transporters influence the availability of glycine for guanidinoacetate synthesis, a precursor of creatine. Transporters such as SLC6A8 and monocarboxylate transporter 12 (MCT12) participate in creatine and guanidinoacetate flux in the kidney and brain, linking glycine transport to creatine deficiency syndromes. This article synthesizes authoritative QuickGO annotation data and verified PubMed literature to provide a research-grade overview of glycine transport, its genes, disease relevance, and experimental models for CRISPR-based investigation.

GO:0015816 glycine transport is defined by the Gene Ontology as the directed movement of glycine, also known as aminoethanoic acid, into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. In practical terms, this process includes the uptake of glycine from the extracellular space by sodium- and chloride-coupled transporters, its release from intracellular stores, and its flux across organelle membranes. The term is a biological process and does not refer to a single protein; rather, it encompasses the coordinated action of multiple transporters, channels, and regulatory proteins that determine glycine gradients in tissues such as the central nervous system, kidney, and liver.

Glycine transport is essential for terminating glycinergic inhibitory neurotransmission and for maintaining the glycine co-agonist pool required for NMDA receptor activation. Pharmacological inhibition of GlyT1 elevates synaptic glycine and has been pursued as a therapeutic strategy for schizophrenia, while GlyT2 inhibitors are investigated for analgesia. Beyond the nervous system, glycine transport contributes to creatine biosynthesis and renal guanidinoacetate handling, and its disruption is linked to inherited metabolic disorders. Because glycine transport proteins are druggable membrane targets with well-characterized pharmacology, they represent a fertile area for CRISPR-based functional genomics and therapeutic development.

The following genes encode transporters, enzymes, and regulatory proteins directly implicated in glycine transport and its metabolic coupling.

Glycine transport is regulated at multiple levels. Transcriptional control of SLC6A9 and SLC6A5 determines transporter abundance in glia and neurons, respectively. Post-translational modifications, including phosphorylation and glycosylation, influence transporter trafficking and surface expression. Membrane cholesterol content directly modulates GlyT2 inhibition and substrate transport, indicating that lipid microdomains act as regulatory hubs. Additionally, the metabolic demand for glycine in creatine synthesis and heme production can indirectly regulate transport activity through substrate availability and feedback mechanisms involving AGAT and GAMT. Pharmacological agents such as GlyT1 inhibitors can acutely modulate transport function, and their effects are influenced by the lipid environment.

Glycine transport is directly implicated in schizophrenia pathophysiology because GlyT1 regulates the concentration of glycine at NMDA receptors. Hypofunction of NMDA receptors is a leading hypothesis for schizophrenia, and increasing synaptic glycine by inhibiting GlyT1 has been investigated as a symptom-modifying strategy. Clinical trials of GlyT1 inhibitors such as bitopertin have shown mixed results, but the mechanism remains a major focus of drug discovery. Genetic and pharmacological studies continue to explore how SLC6A9 variants and transporter expression levels influence disease risk and treatment response.

Mutations in SLC6A5, which encodes GlyT2, cause hyperekplexia, a neurological disorder characterized by exaggerated startle responses and stiffness in infants. Loss of GlyT2 function impairs glycine reuptake at inhibitory synapses, leading to reduced vesicular glycine stores and disrupted glycinergic inhibition. This condition highlights the critical role of glycine transport in motor control and demonstrates that transporter dysfunction can produce severe neurological phenotypes. Research on GlyT2 mutants has also informed the development of analgesics targeting this transporter.

Glycine transport intersects with creatine metabolism because glycine is a substrate for AGAT (encoded by GATM) in the first step of creatine synthesis. Mutations in SLC6A8, GATM, or GAMT cause creatine deficiency syndromes with neurological symptoms including intellectual disability and seizures. Transporters such as MCT12 (SLC16A12) mediate guanidinoacetate efflux in the kidney, and their dysfunction can alter glycine and guanidinoacetate homeostasis. These disorders illustrate how glycine transport is embedded in systemic metabolic networks beyond neurotransmission.

GlyT2 is a promising target for analgesic development because inhibition of this transporter enhances glycinergic inhibition in the spinal cord, reducing pain transmission. Structural studies of GlyT2 with analgesic compounds have revealed the binding sites and mechanisms of action for novel inhibitors. Membrane cholesterol modulates the efficacy of these inhibitors, suggesting that lipid composition may influence analgesic drug responses. This area represents a direct therapeutic application of glycine transport research.

Direct measurement of glycine transport activity is typically performed using radiolabeled [3H]glycine uptake assays in cells expressing recombinant transporters or in primary cultures. These assays quantify the rate of substrate accumulation and allow determination of kinetic parameters such as Km and Vmax. Fluorescent glycine analogs and genetically encoded sensors have also been developed to monitor transport in real time. Such methods are essential for validating CRISPR-generated transporter mutants.

Because glycine transporters are electrogenic, electrophysiological recordings can measure transport-associated currents in Xenopus oocytes or mammalian cells expressing GlyT1 or GlyT2. Patch-clamp and two-electrode voltage-clamp techniques reveal ion coupling stoichiometry, voltage dependence, and inhibitor effects. These approaches are particularly useful for studying point mutations that alter transport function without affecting surface expression.

Cryo-electron microscopy has provided high-resolution structures of GlyT1 and GlyT2 in multiple conformational states, revealing substrate binding pockets and inhibitor sites. These structures guide mutagenesis and drug design by identifying residues critical for transport and allosteric modulation. Structural studies also show how cholesterol binds to GlyT2 and modulates its activity.

Genome-wide CRISPR knockout or activation screens can identify genes that regulate glycine transport, including transporters, metabolic enzymes, and trafficking factors. Such screens typically use glycine-dependent cell viability or fluorescent glycine sensors as readouts. Hits from these screens can be validated with targeted knockout or overexpression models to establish causality.

Researchers studying glycine transport-related genes often need to determine whether a candidate gene is causally involved in glycine flux, neurotransmission, or metabolic disease. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions with publication-grade rigor.

Glycine transport (GO:0015816) is a fundamental biological process that controls glycine availability for neurotransmission, metabolism, and creatine synthesis. The SLC6 family transporters GlyT1 and GlyT2 are central to this process, and their dysfunction is linked to schizophrenia, hyperekplexia, and creatine deficiency syndromes. Structural and pharmacological advances continue to reveal how these transporters work and how they can be targeted therapeutically. CRISPR-based models are accelerating research into glycine transport by enabling precise knockout, knock-in, and point mutation studies in relevant cell types. EDITGENE offers comprehensive services to generate these models and support functional genomics, drug discovery, and mechanistic studies in glycine transport biology.